FrancophonIA/ELRC3.0 huggingface dataset:
English: Low white blood cell count (leukopenia or neutropenia), muscle pain, temporal partial hair loss (alopecia), abdominal distension (feeling bloated), diarrhoea, dizziness, injection site reaction or swelling, disturbed taste, pain in the site of injection, headache, high or low blood pressure, peripheral oedema, abnormal results of renal blood test (increased creatinine), abdominal pain (general and upper), constipation, abnormal results of liver blood test, flushing and hot flushes, increased sugar level in the blood, fainting, renal failure (including acute injury), dehydration, heartburn (dyspepsia), blood in urine, abnormal results of urine test (presence of serum proteins), decrease in function of thyroid, shortness of breath, inflammation of stomach (gastritis), abnormally high amounts of bile pigment (bilirubin) in the blood (Hyperbilirubinemia), abnormal results of blood test (Hypomagnesaemia and hyponatraemia), influenza like illness, chills, bone marrow cancer (myelodysplastic syndrome), blood transfusion.
Danish: Almindelig (kan påvirke op til 1 ud af 10 personer) Lavt antal hvide blodlegemer (leukopeni eller neutropeni), muskelsmerter, midlertidigt delvist hårtab (alopeci), abdominal distension (oppustethed), diarré, svimmelhed, reaktion på injektionsstedet eller hævelse, smagsforstyrrelser, smerte på injektionsstedet, hovedpine, højt eller lavt blodtryk, perifert ødem, unormale resultater af nyretest (forhøjet kreatinin), mavesmerter (generelt og øvre), forstoppelse, unormale resultater af levertest, rødme og hedeture, øget sukkerindhold i blod, besvimelse, nyresvigt (herunder akut skade), dehydrering, halsbrand (dyspepsi), blod i urinen, unormale urinprøveresutater (forekomst af serumproteiner), nedsat funktion af skjoldbruskkirtlen, åndenød, mavebetændelse (gastritis ), unormalt høje mængder galpigment (bilirubin) i blodet (hyperbilirubinæmi), unormale blodprøveresultater (hypomagnesæmi og hyponatriæmi), influenzalignende sygdom, kuldegysninger, knoglemarvscancer (myelodysplastisk syndrom), blodtransfusion.
English: Acetic acid, sodium acetate, gentisic acid, ascorbic acid, pentetic acid, sodium chloride 9 mg/mL injection, sodium hydroxide, water for injections.
Danish: Eddikesyre, natriumacetat, gentisinsyre, ascorbinsyre, pentinsyre, natriumchlorid 9 mg/ml injektion, natriumhydroxid, vand til injektionsvæsker.
English: Each vial contains a volume varying from 20.5 to 25.0 mL of solution corresponding to an activity of 7,400 MBq at date and time of infusion.
Danish: Hvert hætteglas indeholder et volumen varierende fra 20,5 til 25,0 ml opløsning svarende til en aktivitet på 7.400 MBq på dato og tidspunkt for infusion.
English: - The other ingredients are: acetic acid, sodium acetate, gentisic acid, ascorbic acid, diethylene triamine pentaacetic acid (DTPA), sodium chloride 9 mg/mL (0.9%) solution for injection, water for injections (see section 2 “Lutathera contains sodium”).
Danish: - Øvrige indholdsstoffer: Eddikesyre, natriumacetat, gentisinsyre, ascorbinsyre, diethylentriaminpentaeddikesyre (DTPA), natriumchlorid 9 mg/ml (0,9 %) injektionsvæske, opløsning, vand til injektionsvæsker (se afsnit 2 "Lutathera indeholder natrium ”).
English: What Lutathera looks like and contents of the pack Lutathera is a clear and colourless solution for infusion, supplied in a colourless glass vial closed with a rubber stopper and sealed with an aluminium capsule.
Danish: Lutathera er en klar og farveløs infusionsvæske, der leveres i et farveløst hætteglas lukket med en gummiprop og forseglet med en aluminiumskapsel.
English: Neoplasms benign, malignant and unspecified (including cysts and polyps)
Danish: Benigne, maligne og uspecificerede neoplasmer (inkl.
English: Action
Danish: Tiltag
English: • Kidney failure with creatinine clearance < 30 mL/min
Danish: • Nyresvigt med kreatinin-clearance < 30 ml/min
English: PFS and OS observed in the Erasmus phase I/II study in Dutch patients with GEP and bronchial NET - (FAS, N=360)
Danish: PFS og OS observeret i Erasmus fase I/II-studiet hos hollandske patienter med GEP og bronkial NET - (FAS, N = 360)
English: Breast-feeding must be stopped.
Danish: Amning skal stoppes.
English: Swelling face Hyperhidrosis Pruritus generalized
Danish: Hævet ansigt Hyperhidrose Generaliseret pruritus
English: The hazard ratio for Lutathera was 0.21 (95% CI: 0.14 - 0.33), indicating 79% reduction in the risk for a patient to progress or die under Lutathera compared to octreotide LAR.
Danish: Hazard ratioen for Lutathera var 0,21 (95 % CI: 0.14 - 0.33), hvilket indikerede en reduktion på 79 % for, at en patient ville progrediere eller dø under behandling med Lutathera, sammenlignet med octreotid LAR.
English: Oropharyngeal pain Pleural effusion Sputum increased Choecking sensation
Danish: Orofaryngeal smerte Pleuraeffusion Forøget sputum Kvælningsfornemmelse
English: The medicinal product should be infused through an intravenous catheter placed in the vein exclusively for its infusion.
Danish: Lægemidlet skal injiceres via et intravenøst kateter placeret i venen udelukkende til infusion af dette.
English: 8 Includes Arthralgia, Pain in extremity, Back pain, Bone pain, Flank pain, Musculoskeletal chest pain and Neck pain
Danish: 8 Omfatter ledsygdom, smerter i ekstremitet, rygsmerter, knoglesmerter, flankesmerter, muskuloskeletale brystsmerter og nakkesmerter
English: How Lutathera is used 4.
Danish: Sådan får du Lutathera 4.
English: If necessary, patients may be treated with short acting somatostatin analogues during the 4 weeks preceding Lutathera administration, until 24 hours before the administration of Lutathera.
Danish: Om nødvendigt kan patienterne behandles med korttidsvirkende somatostatinanaloger i 4 uger før administration af Lutathera og op til 24 timer før administration af Lutathera.
English: - If you get any side effects, talk to your nuclear medicine doctor.
Danish: Hvis du oplever nogen bivirkninger, skal du tale med din nuklearmedicinske læge.
English: Osteogenic Cells Skin
Danish: Osteogene celler
English: This evidence confirms what has been previously observed in the Erasmus phase I/II study, in which HPLC analysis of a urine specimen collected 1 hour post administration of lutetium (177Lu) oxodotreotide from one patient receiving 1.85 MBq of lutetium (177Lu) oxodotreotide indicated that the main portion (91%) was excreted unchanged.
Danish: Denne evidens bekræfter det, der tidligere er blevet observeret i Erasmus fase I/II-studiet, hvor HPLCanalyse af en urinprøve indsamlet 1 time efter administration af lutetium (177Lu)-oxodotreotid fra en patient, der modtog 1,85 MBq lutetium (177Lu)-oxodotreotid viste, at hovedparten (91 %) udskilles uændret.
English: 6.2 Incompatibilities
Danish: 6,2 Uforligneligheder
English: • Renal or urinary tract morphological abnormalities;
Danish: • Morfologiske anormaliteter i nyrer eller urinveje;
English: Staphylococcal infections Streptococcal bacteraemia
Danish: Stafylokokinfektioner Streptokokbakteriæmi
English: OS median was 27.4 months in octreotide LAR arm and was not reached in Lutathera arm. An update conducted about one year after (30 June 2016) showed similar trend with 28 deaths in the Lutathera arm and 43 in octreotide LAR 60 mg arm, an HR of 0.536, and a median OS of 27.4 months in octreotide LAR arm and still not reached in Lutathera arm.
Danish: En opdatering gennemført omkring et år efter den 30. juni 2016 viste en lignende tendens med 28 dødsfald i Lutathera-armen og 43 i octreotid LAR 60 mg-armen, et HR på 0,536 og et median OS på 27,4 måneder i octreotid LAR-armen og var stadig ikke pnået i Lutathera-armen.
English: Hypertension7 Flushing Hot flush Hypotension
Danish: Hypertension7 Rødmen Hedeture Hypotension
English: Administered agents
Danish: Administrerede midler
English: Nausea, vomiting, fatigue, low platelet count (thrombocytopenia), low white blood cell count (lymphopenia), low red cell count (anaemia), decreased appetite, decreased all blood cell count (pancytopenia)
Danish: Kvalme, opkastning, træthed, lavt blodpladeantal (trombocytopeni), lavt antal hvide blodlegemer (lymfopeni), lavt antal røde blodlegemer (anæmi), nedsat appetit, nedsat antal blodlegemer (pancytopeni)
English: Amount
Danish: Mængde
English: Bronchial Pancreatic Foregut** Midgut Hindgut
Danish: Bronkial Bugspytkirtel Fortarm** Midttarm Bagtarm
English: Keep the specific plastic trash bags separated from the other trash; keep the bags away from children and animals.
Danish: Hold poserne væk fra børn og dyr.
English: Marketing Authorisation Holder Advanced Accelerator Applications 20 rue Diesel
Danish: Indehaver af markedsføringstilladelsen Advanced Accelerator Applications 20 rue Diesel
English: Best response, ORR and DoR observed in the Erasmus phase I/II study in Dutch patients with GEP and bronchial NETs - (FAS, N=360)
Danish: Tabel 10: Bedste respons, ORR og DoR observeret i Erasmus fase I/ II-studiet hos hollandske patienter med GEP og bronkiale NET - (FAS, N = 360)
English: − A pair of tongs (for Lutathera vial handling)
Danish: − En tang (til håndtering af Lutathera-hætteglas)
English: Blood catecholamines c-reactive protein increased
Danish: Øget blodkreatinfosfokinase Øget blodlaktatdehydrogenase Blodkatecholaminer Øget C-reaktivt protein
English: There is evidence , from the analysis of urine samples of 20 patients included in the NETTER-1 phase III Dosimetry, pharmacokinetic and ECG substudy, that lutetium (177Lu) oxodotreotide is poorly metabolized and is excreted mainly as intact compound by renal route.
Danish: Analyse af urinprøver af 20 fra patienter inkluderet i NETTER - 1-fase III dosimetri, farmakokinetisk og EKG-substudiet indikerer, at lutetium (177Lu)-oxodotreotid metabliseres dårligt og hovedsageligt udskilles som intakt forbindelse gennem nyrerne.
English: The PFS Kaplan-Meier graph for the full analysis set (FAS) at the cut-off date 30 June 2016 is depicted in Figure 4.
Danish: PFS Kaplan - Meier-grafen for det fulde analysesæt (FAS) ved skæringsdatoen den 30. juni 2016 er afbildet i Figur 4
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING LEAD SHIELDING CONTAINER
Danish: MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE BEHOLDER MED BLYAFSKÆRMNING
English: • Kidney failure with creatinine clearance < 50 mL/min;
Danish: • Nyresvigt med kreatinin-clearance < 50 ml/min;
English: • Hypersensitivity to the active substance, to any of the excipients listed in section 6.1.
Danish: • Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt.
English: During the infusion, the flow of sodium chloride 9 mg/mL (0.9%) solution for injection increases the pressure in the Lutathera vial, facilitating the flow of Lutathera into the catheter inserted in the patient's peripheral vein.
Danish: Under infusionen øger tilførslen af natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning trykket i Lutathera-hætteglasset, hvilket fremskynder tilførslen af Lutathera til det forhåndsanlagte venøse kateter i patientens arm.
English: The volume of sodium chloride 9 mg/mL (0.9%) solution for injection necessary to complete the infusion may vary.
Danish: Den nødvendige volumen af natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning til fuldførelse af infusionen kan variere.
English: Lysine
Danish: Lysin
English: What Lutathera contains - The active substance is lutetium (177Lu) oxodotreotide.
Danish: Lutathera indeholder følgende: - Aktivt stof: lutetium (177Lu)-oxodotreotid.
English: The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting etc.
Danish: Ved administration af radioaktive lægemidler udsættes andre personer for risiko for ydre bestråling eller kontaminering fra spild af urin, opkast, blod osv. Der skal derfor træffes forholdsregler til beskyttelse mod stråling i overensstemmelse med nationale bestemmelser.
English: Tabulated list of adverse reactions The adverse reactions are listed in Table 7 according to the frequency and the MedDRA System Organ
Danish: Tabel over bivirkninger Bivirkningerne er angivet i henhold til hyppigheden og systemorganklasse iht.
English: For patient preparation, see section 4.4.
Danish: 4.4 for anvisninger i forberedelse af patienten.
English: To continue Lutathera infusion, it is mandatory to use a new catheter possibly placing it in a contralateral venous access.
Danish: Før Lutathera-infusionen genoptages er det påkrævet at anvende et nyt kateter og, om muligt, at anlægge det til modsidig, venøs adgang.
English: The patient should be encouraged to urinate as much as possible after Lutathera adminiastration.
Danish: Patienten skal opfordres til at lade vandet så ofte som muligt efter administration med Lutathera.
English: Genetic consultation is recommended if the patient wishes to have children after treatment.
Danish: hvis patienten ønsker at få børn efter behandling.
English: Volumetric activity at calibration time: 370 MBq/mL - {DD/MM/YYYY hh:mm UTC}
Danish: Volumetrisk aktivitet på kalibreringstidspunktet: 370 MBq/ml - {DD/MM/ÅÅÅÅ tt:mm UTC}
English: Pregnancy No studies on animal reproductive function have been conducted with lutetium (177Lu) oxodotreotide.
Danish: Graviditet Der er ikke foretaget undersøgelser af dyrs reproduktive funktion med lutetiumoxodotreotid (177Lu).
English: No animal studies have been performed to determine the effects of lutetium (177Lu) oxodotreotide on the fertility of either gender.
Danish: Der er ikke udført dyreforsøg for at bestemme virkningerne af lutetiumoxodotreotid (177Lu) på fertiliteten hos begge køn.
English: Nevertheless, if the physician decides to start the treatment, clear information should be given to the patient regarding the risks associated with the administration of Lutathera.
Danish: Ikke desto mindre bør der videregives utvetydig information til patienten om risici forbundet med administration af Lutathera, hvis lægen beslutter sig for at starte behandlingen.
English: Lutathera vial tubing connections procedure (see Figure 2):
Danish: Forbindelse af slanger til Lutathera-hætteglas (se Figur 12):
English: Careful consideration of the activity to be administered to patients with hepatic impairment is required since an increased radiation exposure is possible in these patients.
Danish: Nøje afvejning af den administrerede aktivitet hos patienter med leverbeskadigelse er nødvendig, da der er mulighed for øget strålingseksponering.
English: Concomitant use of cold somatostatin analogues may be needed for disease symptoms control.
Danish: Ledsagende behandling med somatostatinanaloger Ledsagende behandling med kolde somatostatinanaloger kan være nødvendigt for at behandle visse sygdomssymptomer.
English: See leaflet for further information.
Danish: Se indlægssedlen for yderligere oplysninger
English: Excipient with known effect Each mL of solution contains 0.14 mmol (3.2 mg) of sodium.
Danish: Hjælpestof(fer), som behandleren skal være opmærksom på Hver ml opløsning indeholder 0,14 mmol (3,2 mg) natrium.
English: If necessary, patients may be treated with short acting somatostatin analogues during the 4 weeks until 24 hours preceding Lutathera administration.
Danish: Om nødvendigt kan patienterne behandles med korttidsvirkende somatostatinanaloger i 4 uger før administration af Lutathera og op til 24 timer før administration.
English: Lutathera should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings (see section 6.6) and after evaluation of the patient by a qualified physician.
Danish: Luthatera må kun administreres af personer, som har autorisation til at arbejde med radioaktive lægemidler i et dertil egnet klinisk miljø (se pkt.
English: To avoid treatment-related nausea and vomiting, an intravenous bolus of an antiemetic medicinal product should be injected 30 minutes before the start of amino acid solution infusion (see section
Danish: For at undgå behandling-relateret til kvalme og opkastning bør der injiceres en intravenøs bolusindsprøjtning med antiemetika 30 minutter før påbegyndt med aminosyreopløsningsinfusion (se pkt.
English: The PFS Kaplan-Meier graph for the full analysis set (FAS) at the cut-off date 24 July 2015 is depicted in Figure 3.
Danish: PFS Kaplan - Meier-grafen for det fulde analysesæt (FAS) ved skæringsdatoen den. 24 juli 2015 er afbildet i Figur 3.
English: See the end of section 4 for how to report side effects.
Danish: 4 hvordan De indberetter bivirkninger.
English: See Table 5.
Danish: Se Tabel 5.
English: Additionally, due to the death and breakage of the malignant cells by the therapy, there is a possibility that you experience an excessive release of hormones from these cells increasing or triggering neuroendocrine tumour related symptoms such as diarrhoea, flushing and hot flushes, heartbeat disorder, shortness of breath, etc. Should you experience such symptoms: inform your doctor immediately, who may request that you stay at the hospital for observation and treatment if necessary.
Danish: På grund af terapiens nedbrydnings- og ødelæggelse af de maligne celler (celledød) er der desuden en mulighed for, at du oplever en overdreven frigivelse af hormoner fra disse celler, der øger eller udløser neuroendokrine tumorrelaterede symptomer såsom diarré, rødme og hedeture, hjerteslagsforstyrrelse, stakåndethed osv.
English: Lutathera must not be used after the expiry date which is stated on the label after EXP. Store below 25 ºC.
Danish: Lutathera må ikke anvendes efter den udløbsdato, som er anført på pakningen.
English: Osmolarity
Danish: Osmolaritet
English: Hypoglycaemia Hypernatremia Hypophosphatemia Tumor lysis syndrome Hypercalcaemia Hypocalcaemia Hypoalbuminaemia Metabolic acidosis
Danish: Hypoglykæmi Hypernatriæmi Hypofosfatæmi Tumorlysesyndrom Hypercalcæmi Hypocalcæmi Hypoalbuminæmi Metabolisk acidose
English: The infusion of the amino acid solution should start 30 minutes prior to start of Lutathera infusion.
Danish: Infusionen af aminosyreopløsningen skal påbegyndes 30 minutter inden start af infusion af Lutathera.
English: Breast-feeding It is unknown whether lutetium (177Lu) oxodotreotide is excreted in breast milk.
Danish: Amning Det er uvist, om lutetium (177Lu)-oxodotreotid udskilles i modermælk.
English: − One bag of sodium chloride 9 mg/mL (0.9%) solution for injection (500 mL)
Danish: − En pose med natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning (500 ml)
English: • The infusion set should be connected to the bag of sodium chloride 9 mg/mL (0.9%) solution for injection and pre-filled by opening the clamp.
Danish: • Infusionssættet forbindes med posen med natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning og forfyldes ved at åbne for klemmen.
English: The vial is enclosed within a lead container for protective shielding.
Danish: Hætteglasset er indesluttet i en blybeholder for beskyttende afskærmning.
English: If at any time in the preparation of this medicinal product the integrity of this container and vial is compromised it should not be used.
Danish: Hvis hætteglassets eller emballagens integritet på noget tidspunkt brydes under klargøring af lægemidlet, må det ikke anvendes.
English: • The tubing line should be pre-filled with sodium chloride 9 mg/mL (0.9%) solution for injection and then connected with a venous catheter previously inserted to the patient's arm.
Danish: • Slangeforbindelsen forfyldes med natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning og forbindes derefter med et forhåndsanlagt venøst kateter i patientens arm.
English: For instructions on the medicinal product before administration, see section 12.
Danish: 12 for anvisninger i fortynding af lægemidlet før administration.
English: Urinary incontinence Glomerular filtration rate decreased Renal disorder
Danish: Urininkontinens Nedsat glomerulær filtrationshastighed Nyresygdom Akut prærenalt svigt Nyrebeskadigelse
English: Any unused medicinal product or waste material should be disposed of in accordance with local requirements (see section 6.6).
Danish: Ikke-anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer (se pkt.
English: Lutathera with sodium chloride 9 mg/mL (0.9%) solution for injection
Danish: Lutathera med natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning
English: Hormonal crises
Danish: Hormonforstyrrelser
English: Clear, colourless to slightly yellow solution.
Danish: Klar, farveløs til lysegul opløsning.
English: For instruction on preparation of the medicinal product before administration, see section 12.
Danish: For instruktioner om radioaktiv mærkning af lægemidlet før administration henvises til pkt.
English: Hyperglycaemia Dehydration Hypomagnesaemia Hyponatremia
Danish: Hyperglykæmi Dehydrering Hypomagnesæmi Hyponatriæmi
English: There is no relevant use of Lutathera in the paediatric population in the indication of treatment of GEP-NETs (excluding neuroblastoma, neuroganglioblastoma, phaeochromocytoma).
Danish: Der findes ingen relevant anvendelse af Lutathera i den pædiatriske population til indiceret behandling af GEP-NET (undt.
English: Pancreatic enzymes decreased Hepatocellular injury Cholestasis
Danish: Reducerede pankreasenzymer Hepatocellulær skade Kolestase
English: Leukocyturia
Danish: Leukocyturi
English: Dry mouth
Danish: Tør mund Flatulens
English: Hepatic encephalopathy Paraesthesia Parosmia
Danish: Hepatisk encefalopati Paræstesi
English: Acetic acid Sodium acetate Gentisic acid Ascorbic acid Pentetic acid Sodium chloride Sodium hydroxide Water for injections
Danish: Eddikesyre Natriumacetat Gentisinsyre Ascorbinsyre Pentetsyre Natriumchlorid Natriumhydroxid Vand til injektion
English: Any unused medicinal product or waste material should be disposed according to local requirements.
Danish: Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer.
English: • Haematology (Haemoglobin [Hb], white blood count, platelet count)
Danish: • Hæmatologi (Hæmoglobin [Hb], leukocyttal, trombocyttal)
English: An individual benefit-risk assessment is recommended prior to treatment with Lutathera in patients with mild and moderate renal impairment, for additional details see section 4.2 (Table 3) and section 4.4.
Danish: En individuel vurdering af fordele og risici anbefales før behandling med Lutathera hos patienter med let og moderat nedsat nyrefunktion, for yderligere oplysninger henvises til pkt.
English: Storage of the vial
Danish: Opbevaring af hætteglasset
English: Disposable waterproof gloves should be worn.
Danish: Der bør anvendes vandtætte handsker til engangsbrug.
English: Orthostatic hypotension Phlebitis
Danish: Ortostatisk hypotension Flebitis
English: Thrombocytopenia2 Lymphopenia3
Danish: Blod og lymfesystem Trombocytopeni2 Lymfopeni3
English: Bone marrow function and/or blood count disorders Because of the potential for undesirable effects, blood counts must be monitored at baseline and during treatment, and until resolution of any eventual toxicity (see section 4.2).
Danish: På grund af muligheden for bivirkninger skal patienternes trombocyt- og leukocyttal monitoreres ved baseline og under behandlingen og indtil en eventuel toksicitet er fastslået (se pkt.
English: The vial is enclosed within a plastic sealed, lead shielded container.
Danish: Hætteglasset er lukket inde i en plastforseglet, blybeskyttet beholder.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL
Danish: MINDSTEKRAV TIL MÆRKNING PÅ SMÅ INDRE EMBALLAGER (Hætteglas 2)
English: METHOD OF ADMINISTRATION Single-dose vial.
Danish: ADMINISTRATIONSMETODE Hætteglas med enkelt dosis
English: therefore treatment with Lutathera in those patients is not recommended.
Danish: oxodotreotid hos patienter med svær leverbeskadigelse er ikke blevet undersøgt, og derfor anbefales det ikke at behandle disse patienter med Lutathera.
English: Posology
Danish: Parosmi
English: Clavicle fracture
Danish: Kravebensfraktur
English: Pancreatitis acute Rectal haemorrhage Melaena
Danish: Akut pancreatitis Rektal blødning Melæna
English: NAME OF THE MEDICINAL PRODUCT Lutathera 370 MBq/mL solution for infusion
Danish: LÆGEMIDLETS NAVN Lutathera 370 MBq/ml infusionsvæske, opløsning